For U.S. Residents Only 
CABLIVI is used together with a procedure called plasma exchange and medication called immunosuppressive therapy to treat aTTP/iTTP* in adults. CABLIVI has an active ingredient called caplacizumab-yhdp (cap-luh-siz-uh-mab). It is a small protein that is meant to prevent your body from forming dangerous blood clots during an aTTP/iTTP episode.
Plasma exchange is a procedure that removes and replaces a person's blood plasma. This process helps clean your blood by removing things you have too much of (such as immune cells) and adding things you have too little of (such as ADAMTS13 enzymes and platelets).
Immunosuppressants are medicines that help decrease the activity of your immune system, which is overactive during an episode of aTTP/iTTP.
CABLIVI is the first FDA-approved treatment for adult aTTP/iTTP patients. When combined with PEX and immunosuppressive therapy, it helps stop platelets from sticking to vWF and helps prevent your body from forming dangerous blood clots during an aTTP/iTTP episode.
Watch now for information about how CABLIVI helps fight against aTTP/iTTP.
Acquired thrombotic thrombocytopenic purpura, called aTTP, is a very rare, potentially life-threatening blood clotting disorder. It's unknown why anyone develops aTTP, and everyone's experience with aTTP is different. For many, aTTP is a lifelong condition. In fact, in one study of 21 patients with aTTP over 30 years, 90% of these patients who had one aTTP event had another, called a recurrence. It's important to note that every aTTP event is considered a medical emergency that can result in serious complications, including death.
Treatment for adults with aTTP can include a procedure called plasma exchange and a type of medication called immunosuppressants. During an aTTP event, patients may experience a variety of symptoms, including bleeding from the gums or nose, dark bruises or dots on the skin, blood in urine, stomach pain, chest pain, seizures, headaches, confusion, and tiredness.
aTTP occurs when your immune system blocks the natural
function of a protein in the blood called ADAMTS13. Normally, ADAMTS13 cuts
another protein, called von Willebrand factor or vWF, into smaller pieces. vWF
sticks to an important component of blood, called platelets, to form clots when
bleeding occurs. In aTTP patients, there are more long pieces of vWF in
circulation than normal because ADAMTS13 isn't working correctly. As a result,
these longer pieces of vWF attract more platelets than normal, causing blood
clots to form easily throughout the body. These clots decrease the number of
platelets in the body, a condition called thrombocytopenia, and can lead to
uncontrolled bleeding.
CABLIVI can help adults in the fight against aTTP when used in combination with
plasma exchange and immunosuppressive therapy. Plasma exchange helps filter your
blood by removing things you have too much of that can cause clotting, like vWF,
and adding things you have too little of, like ADAMTS13. Immunosuppressants help
decrease the activity of your immune system, which is overactive during an event
of aTTP.
CABLIVI was specifically developed to reduce platelet binding to vWF in aTTP. CABLIVI sticks to vWF, making it harder for platelets to attach. This helps stop the uncontrolled formation of dangerous blood clots during an aTTP event.
CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Do not take CABLIVI if you've had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.
Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take, including medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
Talk to your doctor before scheduling any surgery, medical or dental procedure.
CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. In the post-marketing setting, cases of life-threatening and fatal bleeding were reported in patients receiving CABLIVI. Contact your doctor immediately if symptoms of excessive bruising, excessive bleeding, or major bleeding occur. Signs and symptoms of bleeding include: pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness.
You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.
The most common side effects include nosebleed, headache and bleeding gums.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.
Alex, real patient. Individual results may vary.
Alex is being compensated by Sanofi.
Do not take CABLIVI if you've had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.
CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Do not take CABLIVI if you've had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.
Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take, including medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
Talk to your doctor before scheduling any surgery, medical or dental procedure.
CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. In the post-marketing setting, cases of life-threatening and fatal bleeding were reported in patients receiving CABLIVI. Contact your doctor immediately if symptoms of excessive bruising, excessive bleeding, or major bleeding occur. Signs and symptoms of bleeding include: pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness.
You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.
The most common side effects include nosebleed, headache and bleeding gums.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.
Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.
